Phase I Trial of NPI-0052 Begins

Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

Related Content:

Oncology NEWS International Vol 15 No 6

Triple-Negative Cancers More Common in Young Black Pts

Artists Turn Flowers & Curves Into 'Forms' and 'Figures'

Study to Examine Outcomes Disparities in Pediatric ALL